<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://atvb.ahajournals.org">
<title>Arteriosclerosis, Thrombosis, and Vascular Biology recent issues</title>
<link>http://atvb.ahajournals.org</link>
<description>Arteriosclerosis, Thrombosis, and Vascular Biology RSS feed -- recent issues</description>
<prism:eIssn>1524-4636</prism:eIssn>
<prism:publicationName>Arteriosclerosis, Thrombosis, and Vascular Biology</prism:publicationName>
<prism:issn>1079-5642</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/e151?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1207?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1209?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1211?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1214?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1216?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1219?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1222?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1225?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1237?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1244?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1251?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1257?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1263?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1270?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1277?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1283?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1290?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1296?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1298?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1304?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1311?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1318?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1326?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1332?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1339?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1347?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1355?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1361?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1368?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1375?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1379?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1385?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1392?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1398?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/7/1407?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/e32?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/e150?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1031?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1034?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1036?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1039?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1050?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1060?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1068?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1077?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1084?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1090?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1097?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1104?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1111?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1117?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1123?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1130?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1137?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1144?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1151?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1158?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1165?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1172?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1179?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1186?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1193?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/6/1200?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/e31?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/799?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/801?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/803?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/805?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/807?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/809?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/812?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/820?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/827?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/835?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/841?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/850?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/856?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/863?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/871?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/878?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/886?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/892?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/899?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/906?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/913?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/919?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/925?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/932?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/940?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/947?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/954?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/961?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/968?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/975?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/983?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/990?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/997?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/1005?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/1012?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/1018?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/5/1024?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/e23?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/e25?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/e26?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/e29?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/e30?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/601?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/604?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/606?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/608?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/611?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/615?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/622?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/629?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/637?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/644?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/651?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/658?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/665?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/672?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/678?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/685?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/692?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/698?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/705?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/711?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/718?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/725?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/732?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/739?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/746?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/752?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/758?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/764?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/771?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/777?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/786?rss=1" />
  <rdf:li rdf:resource="http://atvb.ahajournals.org/cgi/content/short/28/4/792?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://atvb.ahajournals.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://atvb.ahajournals.org/icons/banner/title.gif">
<title>Arteriosclerosis, Thrombosis, and Vascular Biology</title>
<url>http://atvb.ahajournals.org/icons/banner/title.gif</url>
<link>http://atvb.ahajournals.org</link>
</image>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/e151?rss=1">
<title><![CDATA[[Corrections] Correction]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/e151?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.133333</dc:identifier>
<dc:title><![CDATA[[Corrections] Correction]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>e151</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>e151</prism:startingPage>
<prism:section>Corrections</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1207?rss=1">
<title><![CDATA[[Editorials] Are the Mechanisms for NO-Dependent Vascular Remodeling Different From Vasorelaxation In Vivo?]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1207?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Schleicher, M., Sessa, W. C.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.167403</dc:identifier>
<dc:title><![CDATA[[Editorials] Are the Mechanisms for NO-Dependent Vascular Remodeling Different From Vasorelaxation In Vivo?]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1208</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1207</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1209?rss=1">
<title><![CDATA[[Editorials] CD36 Goes Native]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1209?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Febbraio, M.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.169342</dc:identifier>
<dc:title><![CDATA[[Editorials] CD36 Goes Native]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1210</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1209</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1211?rss=1">
<title><![CDATA[[Editorials] Adipose Tissue Lymphocytes and Macrophages in Obesity and Insulin Resistance: Makers or Markers, and Which Comes First?]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1211?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bouloumie, A., Casteilla, L., Lafontan, M.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.168229</dc:identifier>
<dc:title><![CDATA[[Editorials] Adipose Tissue Lymphocytes and Macrophages in Obesity and Insulin Resistance: Makers or Markers, and Which Comes First?]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1213</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1211</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1214?rss=1">
<title><![CDATA[[Editorials] A Central Resource for Platelet Proteomics]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1214?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Cagney, G., McRedmond, J.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.167452</dc:identifier>
<dc:title><![CDATA[[Editorials] A Central Resource for Platelet Proteomics]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1215</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1214</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1216?rss=1">
<title><![CDATA[[Editorials] Double Tribble: Two TRIB3 Variants, Insulin, Akt, and eNOS]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1216?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Fleming, I.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.169250</dc:identifier>
<dc:title><![CDATA[[Editorials] Double Tribble: Two TRIB3 Variants, Insulin, Akt, and eNOS]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1218</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1216</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1219?rss=1">
<title><![CDATA[[Editorials] A Novel Role for Adiponectin in the Regulation of Inflammation]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1219?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Ouchi, N., Walsh, K.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165068</dc:identifier>
<dc:title><![CDATA[[Editorials] A Novel Role for Adiponectin in the Regulation of Inflammation]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1221</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1219</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1222?rss=1">
<title><![CDATA[[Editorials] The Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP?]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1222?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Ridker, P. M]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.168989</dc:identifier>
<dc:title><![CDATA[[Editorials] The Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP?]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1224</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1222</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1225?rss=1">
<title><![CDATA[[Brief Reviews] Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1225?rss=1</link>
<description><![CDATA[
<p>Insulin resistance is a key feature of the metabolic syndrome and often progresses to type 2 diabetes. Both insulin resistance and type 2 diabetes are characterized by dyslipidemia, which is an important and common risk factor for cardiovascular disease. Diabetic dyslipidemia is a cluster of potentially atherogenic lipid and lipoprotein abnormalities that are metabolically interrelated. Recent evidence suggests that a fundamental defect is an overproduction of large very low&ndash;density lipoprotein (VLDL) particles, which initiates a sequence of lipoprotein changes, resulting in higher levels of remnant particles, smaller LDL, and lower levels of high-density liporotein (HDL) cholesterol. These atherogenic lipid abnormalities precede the diagnosis of type 2 diabetes by several years, and it is thus important to elucidate the mechanisms involved in the overproduction of large VLDL particles. Here, we review the pathophysiology of VLDL biosynthesis and metabolism in the metabolic syndrome. We also review recent research investigating the relation between hepatic accumulation of lipids and insulin resistance, and sources of fatty acids for liver fat and VLDL biosynthesis. Finally, we briefly discuss current treatments for lipid management of dyslipidemia and potential future therapeutic targets.</p>
]]></description>
<dc:creator><![CDATA[Adiels, M., Olofsson, S.-O., Taskinen, M.-R., Boren, J.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.160192</dc:identifier>
<dc:title><![CDATA[[Brief Reviews] Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1236</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1225</prism:startingPage>
<prism:section>Brief Reviews</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1237?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Temporally Expressed PDGF and FGF-2 Regulate Embryonic Coronary Artery Formation and Growth]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1237?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> PDGF and FGF-2 are important regulators of vascular wall assembly. We tested the hypothesis that their embryonic temporal expression facilitates 2 specific events: (1) the endothelial invasion of the aortic root to form the coronary artery stems and (2) the subsequent growth and development of the arterial tree.</p>
<p><b><I>Methods and Results&mdash;</I></b> Addition of FGF-2 and PDGF-BB proteins to embryonic quail heart explants stimulated a 3- and 7-fold increase, respectively, in tubulogenesis, whereas neutralizing antibodies to these growth factors attenuated tubulogenesis by 40%. Anti&ndash;FGF-2 and anti-PDGF neutralizing antibodies were then introduced in ovo via the vitelline vein at various embryonic (E) days. When injections occurred before coronary ostial formation, the embryos usually developed only 1 coronary artery or lacked coronary arteries. When 1 or both major coronary arteries formed: (1) their branches had a thinner tunica media, and (2) smooth muscle investment did not progress as far distally as in shams. Other anomalies included smaller diameter coronary artery stems in some hearts. Inhibition of VEGF via injections of aflibercept (VEGF-Trap, a VEGFR-1 and -2 chimera), previously shown to be essential for coronary stem formation, limited development of the coronary arteries even though introduced after formation of coronary ostia (at E9 or EI0).</p>
<p><b><I>Conclusions&mdash;</I></b> Our data (1) document a role for FGF-2 and PDGF in the temporal regulation of coronary artery stem formation and growth of the coronary arterial tree and (2) reveal that VEGF expression is required for normal artery/arterial formation, even after coronary artery stem formation.</p>
]]></description>
<dc:creator><![CDATA[Tomanek, R. J., Hansen, H. K., Christensen, L. P.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.166454</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Temporally Expressed PDGF and FGF-2 Regulate Embryonic Coronary Artery Formation and Growth]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1243</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1237</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1244?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Role of Smooth Muscle cGMP/cGKI Signaling in Murine Vascular Restenosis]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1244?rss=1</link>
<description><![CDATA[
<p><b><I>Background&mdash;</I></b> Nitric oxide (NO) is of crucial importance for smooth muscle cell (SMC) function and exerts numerous, and sometimes opposing, effects on vascular restenosis. Although cGMP-dependent protein kinase type I (cGKI) is a principal effector of NO, the molecular pathway of vascular NO signaling in restenosis is unclear. The purpose of this study was to examine the functional role of the smooth muscle cGMP/cGKI signaling cascade in restenosis of vessels.</p>
<p><b><I>Methods and Results&mdash;</I></b> Tissue-specific mouse mutants were generated in which the cGKI protein was ablated in SMCs. We investigated whether the absence of cGKI in SMCs would affect vascular remodeling after carotid ligation or removal of the endothelium. No differences were detected between the tissue-specific cGKI mutants and control mice at different time points after vascular injury on a normolipidemic or apoE-deficient background. In line with these results, chronic drug treatment of injured control mice with the phosphodiesterase-5 inhibitor sildenafil elevated cGMP levels but had no influence on the ligation-induced remodeling.</p>
<p><b><I>Conclusions&mdash;</I></b> The genetic and pharmacological manipulation of the cGMP/cGKI signaling indicates that this pathway is not involved in the protective effects of NO, suggesting that NO affects vascular remodeling during restenosis via alternative mechanisms.</p>
]]></description>
<dc:creator><![CDATA[Lukowski, R., Weinmeister, P., Bernhard, D., Feil, S., Gotthardt, M., Herz, J., Massberg, S., Zernecke, A., Weber, C., Hofmann, F., Feil, R.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.166405</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Role of Smooth Muscle cGMP/cGKI Signaling in Murine Vascular Restenosis]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1250</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1244</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1251?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Androgen Increases AT1a Receptor Expression in Abdominal Aortas to Promote Angiotensin II-Induced AAAs in Apolipoprotein E-Deficient Mice]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1251?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> Castration of male apolipoprotein E&ndash;deficient (apoE<sup>&ndash;/&ndash;</sup>) mice reduces angiotensin II (Ang II)&ndash;induced abdominal aorta aneurysms (AAAs) to that of female mice. The purpose of this study was to determine whether this reduction is attributable to androgen-mediated regulation of aortic Ang II type 1A receptors (AT1aR).</p>
<p><b><I>Methods and Results&mdash;</I></b> AT1aR mRNA abundance in the AAA-prone region of abdominal aortas was 8-fold greater compared to thoracic aortas of male but not female mice. AT1aR mRNA abundance decreased after castration in abdominal but not thoracic aortas of male mice. Dihydrotestosterone (DHT, 0.16 mg/d) administration to castrated male mice restored AT1aR mRNA abundance in abdominal aortas but had no effect in thoracic aortas. DHT also increased AT1aR mRNA abundance in abdominal aortas from female mice. Castrated male or female apoE<sup>&ndash;/&ndash;</sup> mice were administered DHT during infusion of saline or Ang II (1000 ng/kg/min for 28 days). DHT administration did not alter serum cholesterol concentrations, lipoprotein distributions, or atherosclerotic lesion areas in either male or female mice. However, administration of DHT increased AAA incidence in male (27% placebo versus 75% DHT) and female mice (28% placebo versus 64% DHT).</p>
<p><b><I>Conclusions&mdash;</I></b> Androgen promotes AT1aR mRNA abundance in abdominal aortas associated with increased Ang II&ndash;induced AAAs.</p>
]]></description>
<dc:creator><![CDATA[Henriques, T., Zhang, X., Yiannikouris, F. B., Daugherty, A., Cassis, L. A.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.160382</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Androgen Increases AT1a Receptor Expression in Abdominal Aortas to Promote Angiotensin II-Induced AAAs in Apolipoprotein E-Deficient Mice]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1256</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1251</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1257?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Alpha2-Antiplasmin Is a Critical Regulator of Angiotensin II-Mediated Vascular Remodeling]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1257?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> Alpha2-antiplasmin (2-AP) is the major circulating inhibitor of plasmin, which plays a determining role in the regulation of intravascular fibrinolysis. We investigated the role of <SUB>2</SUB>-AP on vascular remodeling in response to angiotensin II (Ang II).</p>
<p><b><I>Methods and Results&mdash;</I></b> 2-AP&ndash;deficient mice were performed. Ang II and <I>N</I><sup></sup>-nitro- L-arginine methyl ester (L-NAME)&ndash;induced perivascular fibrosis was significantly decreased in 2-AP<sup>&ndash;/&ndash;</sup> mice compared with wild-type mice. In situ gelatinolytic activity analysis shows that perivascular gelatinolytic activity was increased in 2-AP<sup>&ndash;/&ndash;</sup> mice, which was responsible for decreased perivascular fibrosis in response to Ang II and L-NAME. Ang II&ndash;induced arterial wall thickening, vascular cell proliferation, apoptosis, c-Myc, and collagen I expression were significantly decreased in 2-AP<sup>&ndash;/&ndash;</sup> mice compared with wild-type mice. Further analysis shows that increased p53 and p21 expression were responsible for inhibition of Ang II&ndash;induced vascular remodeling in 2-AP<sup>&ndash;/&ndash;</sup> mice.</p>
<p><b><I>Conclusion&mdash;</I></b> The results show that 2-AP is a critical regulator for vascular remodeling by inhibiting p53/p21 pathway, suggesting that 2-AP is proposed to be a potential therapeutic target for vascular remodeling.</p>
]]></description>
<dc:creator><![CDATA[Hou, Y., Okada, K., Okamoto, C., Ueshima, S., Matsuo, O.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165688</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Alpha2-Antiplasmin Is a Critical Regulator of Angiotensin II-Mediated Vascular Remodeling]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1262</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1257</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1263?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] SIRT1, a Longevity Gene, Downregulates Angiotensin II Type 1 Receptor Expression in Vascular Smooth Muscle Cells]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1263?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> Resveratrol (3,5,4'-trihydroxystilbene), a polyphenol found in red wine, is known to activate sirtuin1 (SIRT1), a longevity gene. Previous studies have demonstrated that resveratrol extends the life span of diverse species through activation of SIRT1. It was also reported that inhibition of angiotensin II function by angiotensin II type I receptor (AT1R) antagonist prolonged rat life span. We, therefore, hypothesized that resveratrol may inhibit the renin-angiontein system and examined whether resveratrol affects AT1R expression in vascular smooth muscle cells (VSMCs).</p>
<p><b><I>Methods and Results&mdash;</I></b> Northern and Western blot analysis revealed that resveratrol significantly decreased the expression of AT1R at mRNA and protein levels in a dose- and time-dependent manner. Overexpression of SIRT1 reduced AT1R expression whereas nicotinamide, an inhibitor of SIRT1, increased AT1R expression and reversed the resveratrol-induced AT1R downregulation. AT1R gene promoter activity was decreased by resveratrol, but resveratrol did not affect the AT1R mRNA stability. Deletion analysis showed that the most proximal region of AT1R gene promoter containing Sp1 site is responsible for downregulation. Administration of resveratrol suppressed AT1R expression in the mouse aorta and blunted angiotensin II&ndash;induced hypertension.</p>
<p><b><I>Conclusion&mdash;</I></b> Resveratrol suppressed AT1R expression through SIRT1 activation both in vivo and in vitro. The inhibition of the renin-angiotensin system may contribute, at least in part, to the resveratrol-induced longevity and antiatherogenic effect of resveratrol.</p>
]]></description>
<dc:creator><![CDATA[Miyazaki, R., Ichiki, T., Hashimoto, T., Inanaga, K., Imayama, I., Sadoshima, J., Sunagawa, K.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.166991</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] SIRT1, a Longevity Gene, Downregulates Angiotensin II Type 1 Receptor Expression in Vascular Smooth Muscle Cells]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1269</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1263</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1270?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Overexpression of ACE2 Enhances Plaque Stability in a Rabbit Model of Atherosclerosis]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1270?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> The purpose of this study was to test the hypothesis that ACE2 overexpression may enhance atherosclerotic plaque stability by antagonizing ACE activity and converting angiotensin II to angiotensin 1&ndash;7.</p>
<p><b><I>Methods and Results&mdash;</I></b> Atherosclerotic plaques were induced in the abdominal aorta of 114 rabbits by endothelial injury and atherogenic diet. Gene therapy was performed in group A at week 4 and in group B at week 12, respectively. Each group of rabbits were randomly divided into 3 subgroups which received, respectively, a recombinant ACE2 expressing vector (AdACE2), a control vector AdEGFP and AdACE2+A779, an antagonist of angiotensin 1&ndash;7 receptor. Local ACE2 overexpression attenuated the progression of lesions from week 4 to week 8, but not progression of plaque size from week 12 to week 16. In group B rabbits, local ACE2 overexpression resulted in stable plaque compositions, ie, fewer macrophages, less lipid deposition and more collagen contents, higher plaque stability scores, decreased angiotensin II levels, and increased angiotensin 1&ndash;7 levels in plaque tissues in the AdACE2 subgroup compared with those in the AdEGFP subgroup.</p>
<p><b><I>Conclusions&mdash;</I></b> Overexpression of ACE2 results in stabilized atherosclerotic plaques and the mechanism is probably the conversion of vasoconstrictive angiotensin II to vessel protective angiotensin 1&ndash;7.</p>
]]></description>
<dc:creator><![CDATA[Dong, B., Zhang, C., Feng, J. B., Zhao, Y. X., Li, S. Y., Yang, Y. P., Dong, Q. L., Deng, B. P., Zhu, L., Yu, Q. T., Liu, C. X., Liu, B., Pan, C. M., Song, H. D., Zhang, M. X., Zhang, Y.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.164715</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Overexpression of ACE2 Enhances Plaque Stability in a Rabbit Model of Atherosclerosis]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1276</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1270</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1277?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Acute Elevation of Plasma PLTP Activity Strongly Increases Pre-existing Atherosclerosis]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1277?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> A transgenic mouse model was generated that allows conditional expression of human PLTP, based on the tetracycline-responsive gene system, to study the effects of an acute increase in plasma PLTP activity as may occur in inflammation.</p>
<p><b><I>Methods and Results&mdash;</I></b> The effects of an acute elevation of plasma PLTP activity on the metabolism of apolipoprotein B&ndash;containing lipoproteins and on diet-induced pre-existing atherosclerosis were determined in mice displaying a humanized lipoprotein profile (low-density lipoprotein receptor knockout background). Induced expression of PLTP strongly increases plasma VLDL levels in LDL receptor knockout mice, whereas VLDL secretion is not affected. The elevation in plasma triglyceride levels is explained by a PLTP-dependent inhibition of VLDL catabolism, which is caused, at least partly, by a decreased lipoprotein lipase activity. Together with the decreased plasma HDL levels, the acutely increased PLTP expression results in a highly atherogenic lipoprotein profile. Induction of PLTP expression leads to a further increase in size of pre-existing atherosclerotic lesions, even on a chow diet. In addition, the lesions contain more macrophages and less collagen relative to controls, suggesting a less stable lesion phenotype.</p>
<p><b><I>Conclusion&mdash;</I></b> In conclusion, acute elevation of PLTP activity destabilizes atherosclerotic lesions and aggravates pre-existing atherosclerosis.</p>
]]></description>
<dc:creator><![CDATA[Moerland, M., Samyn, H., van Gent, T., van Haperen, R., Dallinga-Thie, G., Grosveld, F., van Tol, A., de Crom, R.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165084</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Acute Elevation of Plasma PLTP Activity Strongly Increases Pre-existing Atherosclerosis]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1282</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1277</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1283?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] CD44 Expressed on Both Bone Marrow-Derived and Non-Bone Marrow-Derived Cells Promotes Atherogenesis in ApoE-Deficient Mice]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1283?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> The purpose of this study was to distinguish the contributions of CD44 expressed on bone marrow&ndash;derived and non&ndash;bone marrow&ndash;derived cells to atherosclerosis.</p>
<p><b><I>Methods and Results&mdash;</I></b> Using bone marrow chimeras, we compared the contributions of CD44 expressed on bone marrow&ndash;derived cells versus non&ndash;bone marrow&ndash;derived cells to the vascular inflammation underlying atherosclerosis. We show that CD44 in both bone marrow&ndash;derived and non&ndash;bone marrow&ndash;derived compartments promotes atherosclerosis in apoE<sup>&ndash;/&ndash;</sup> mice and mediates macrophage and T cell recruitment to lesions in vivo. We also demonstrate that CD44 on endothelial cells (ECs) as well as on macrophages and T cells enhances leukocyte-endothelial cell adhesion and transendothelial migration in vitro. Furthermore, CD44 on vascular smooth muscle cells (VSMCs) regulates their hyaluronan (HA)-dependent migration. Interestingly, in mice lacking CD44 in both compartments, where we observed the least inflammation, we also observed enhanced fibrous cap formation.</p>
<p><b><I>Conclusions&mdash;</I></b> CD44 expressed on bone marrow&ndash;derived and non&ndash;bone marrow&ndash;derived cells both promote atherosclerosis in apoE-deficient mice. Furthermore, CD44 plays a pivotal role in determining the balance between inflammation and fibrosis in atherosclerotic lesions which can impact clinical outcome in humans.</p>
]]></description>
<dc:creator><![CDATA[Zhao, L., Lee, E., Zukas, A. M., Middleton, M. K., Kinder, M., Acharya, P. S., Hall, J. A., Rader, D. J., Pure, E.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165753</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] CD44 Expressed on Both Bone Marrow-Derived and Non-Bone Marrow-Derived Cells Promotes Atherogenesis in ApoE-Deficient Mice]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1289</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1283</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1290?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Mouse CD36 Has Opposite Effects on LDL and Oxidized LDL Metabolism In Vivo]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1290?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> The cluster of differentiation-36 (CD36) is a multifunctional protein which is recognized for its in vitro ability to take up oxidized low-density lipoproteins (oxLDL) in macrophages and is therefore considered atherogenic. It also binds LDL. Our objective was to define the physiological role of CD36 in both native LDL and oxLDL metabolism in mice.</p>
<p><b><I>Methods and Results&mdash;</I></b> Clearance studies of labeled LDL and oxLDL were conducted in wild-type, CD36 knockout (KO), scavenger receptor class B, type I (SR-BI) KO, and SR-BI/CD36 double KO mice. We found that CD36 impedes the disappearance of native LDL and favors that of oxLDL. This was confirmed by association and degradation assays with primary cultures of hepatic cells from wild-type and CD36 KO mice. In addition, our in vivo work indicates that neither SR-BI nor CD36 plays a significant role in cholesteryl esters (CE) selective uptake (SU) from oxLDL, whereas CD36, in absence of SR-BI, can selectively take CE from LDL.</p>
<p><b><I>Conclusion&mdash;</I></b> Our investigation showed for the first time that CD36 plays a significant role in oxLDL uptake in vivo in the mouse. As CD36 also retards LDL clearance, its atherogenic character may also relate to its negative effect on LDL catabolism.</p>
]]></description>
<dc:creator><![CDATA[Luangrath, V., Brodeur, M. R., Rhainds, D., Brissette, L.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.161653</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Mouse CD36 Has Opposite Effects on LDL and Oxidized LDL Metabolism In Vivo]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1295</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1290</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1296?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Cholesterol Absorption From the Intestine Is a Major Determinant of Reverse Cholesterol Transport From Peripheral Tissue Macrophages]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1296?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> We examined the effect of ezetimibe, a cholesterol absorption (CA) inhibitor, and genetic determinants of CA on reverse cholesterol transport (RCT) from subcutaneously injected macrophages using a new dual isotope label technique.</p>
<p><b><I>Methods and Results&mdash;</I></b> Treatment of C57BL/6J mice with ezetimibe decreased dietary CA by 86% and increased RCT from peripheral tissue macrophages (PTM) by 6-fold (<I>P</I>&lt;0.0001). Moreover, congenic 14DKK mice with a modest 41% decrease in dietary CA displayed a 67% increase in RCT from PTM (<I>P</I>&lt;0.007).</p>
<p><b><I>Conclusions&mdash;</I></b> These findings indicate that pharmacological and genetic modifiers of cholesterol absorption are major determinants of reverse cholesterol transport from peripheral tissue macrophages.</p>
]]></description>
<dc:creator><![CDATA[Sehayek, E., Hazen, S. L.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165803</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Cholesterol Absorption From the Intestine Is a Major Determinant of Reverse Cholesterol Transport From Peripheral Tissue Macrophages]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1297</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1296</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1298?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Coexpression of CLA-1 and Human PDZK1 in Murine Liver Modulates HDL Cholesterol Metabolism]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1298?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> In rodents scavenger receptor class B type I (SR-BI) is a key molecule for selective uptake of cholesteryl ester from high-density lipoprotein (HDL). This study was aimed to clarify the role of the human SR-BI/CD36 and LIMP-II Analogues-1 (CLA-1) as a molecular target of selective uptake of cholesteryl ester from HDL in vivo.</p>
<p><b><I>Methods and Results&mdash;</I></b> To clarify the function and regulation of CLA-1 in vivo we produced <I>CLA-1</I> BAC transgenic mice. In spite of abundant hepatic RNA expression of <I>CLA-1</I>, <I>CLA-1</I> BAC transgenic mice had no significant effect on mouse HDL cholesterol. Although coexpression of a human scaffolding protein PDZK1 along with CLA-1 enhanced hepatic CLA-1 expression, it did not affect mouse HDL cholesterol levels, either. However, in the presence of human apoA-1, HDL cholesterol level and size were significantly reduced in CLA-1 transgenic mice, and its reduction was more pronounced in <I>CLA-1/</I>human <I>PDZK1</I> double transgenic mouse.</p>
<p><b><I>Conclusions&mdash;</I></b> We established a mouse model to study human reverse cholesterol transport by expressing <I>CLA-1</I>, human <I>PDZK1</I>, and human <I>apoA-I</I> gene. Our results imply that enhancing CLA-1 expression by human PDZK1 in the liver can modulate HDL cholesterol metabolism and possibly enhance reverse cholesterol transport to prevent the progression of atherosclerosis in human.</p>
]]></description>
<dc:creator><![CDATA[Komori, H., Arai, H., Kashima, T., Huby, T., Kita, T., Ueda, Y.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165845</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Coexpression of CLA-1 and Human PDZK1 in Murine Liver Modulates HDL Cholesterol Metabolism]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1303</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1298</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1304?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] T-lymphocyte Infiltration in Visceral Adipose Tissue: A Primary Event in Adipose Tissue Inflammation and the Development of Obesity-Mediated Insulin Resistance]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1304?rss=1</link>
<description><![CDATA[
<p><b><I>Background&mdash;</I></b> Adipose tissue inflammation may play a critical role in the pathogenesis of insulin resistance (IR). The present study examined the role of lymphocytes in adipose tissue inflammation and IR.</p>
<p><b><I>Methods and Results&mdash;</I></b> In a mouse model of obesity-mediated IR, high-fat diet (HFD) induced IR already after 5 weeks, which was associated with a marked T-lymphocyte infiltration in visceral adipose tissue. In contrast, recruitment of macrophages was delayed with an increase of MAC3-positive staining and F4/80 mRNA expression after 10 weeks of HFD, suggesting a dissociation of macrophage invasion into adipose tissue and IR initiation. In patients with type 2 diabetes, lymphocyte content in adipose tissue biopsies significantly correlated with waist circumference, a marker of IR. Immunohistochemical staining of human adipose tissue revealed the presence of mainly CD4-positive lymphocytes as well as macrophage infiltration. Most macrophages were HLA-DR&ndash;positive, reflecting activation through IFN, a cytokine released from CD4-positive lymphocytes.</p>
<p><b><I>Conclusions&mdash;</I></b> Proinflammatory T-lymphocytes are present in visceral adipose tissue and may contribute to local inflammatory cell activation before the appearance of macrophages, suggesting that these cells could play an important role in the initiation and perpetuation of adipose tissue inflammation as well as the development of IR.</p>
]]></description>
<dc:creator><![CDATA[Kintscher, U., Hartge, M., Hess, K., Foryst-Ludwig, A., Clemenz, M., Wabitsch, M., Fischer-Posovszky, P., Barth, T. F.E., Dragun, D., Skurk, T., Hauner, H., Bluher, M., Unger, T., Wolf, A.-M., Knippschild, U., Hombach, V., Marx, N.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:subject><![CDATA[Animal models of human disease, Type 2 diabetes]]></dc:subject>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165100</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] T-lymphocyte Infiltration in Visceral Adipose Tissue: A Primary Event in Adipose Tissue Inflammation and the Development of Obesity-Mediated Insulin Resistance]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1310</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1304</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1311?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Detection of Neovessels in Atherosclerotic Plaques of Rabbits Using Dynamic Contrast Enhanced MRI and 18F-FDG PET]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1311?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> The association of inflammatory cells and neovessels in atherosclerosis is considered a histological hallmark of high-risk active lesions. Therefore, the development and validation of noninvasive imaging techniques that allow for the detection of inflammation and neoangiogenesis in atherosclerosis would be of major clinical interest. Our aim was to test 2 techniques, black blood dynamic contrast enhanced MRI (DCE-MRI) and 18-fluorine-fluorodeoxyglucose (18F-FDG) PET, to quantify inflammation expressed as plaque neovessels content in a rabbit model of atherosclerosis.</p>
<p><b><I>Methods and Results&mdash;</I></b> Atherosclerotic plaques were induced in the aorta of 10 rabbits by a combination of 2 endothelial abrasions and 4 months hyperlipidemic diet. Six rabbits underwent MRI during the injection of Gd-DTPA, whereas 4 rabbits were imaged after injection of 18F-FDG with PET. We found a positive correlation between neovessels count in atherosclerotic plaques and (1) Gd-DTPA uptake parameters evaluated by DCE-MRI (<I>r</I>=0.89, <I>P</I>=0.016) and (2) 18F-FDG uptake evaluated by PET (<I>r</I>=0.5, <I>P</I>=0.103 after clustered robust, Huber-White, standard errors analysis).</p>
<p><b><I>Conclusion&mdash;</I></b> DCE-MRI and 18F-FDG PET may allow for the evaluation of inflammation in atherosclerotic plaques of rabbits. These noninvasive imaging modalities could be proposed as clinical tools in the evaluation of lesion prognosis and monitoring of anti&ndash;angiogenic therapies.</p>
]]></description>
<dc:creator><![CDATA[Calcagno, C., Cornily, J.-C., Hyafil, F., Rudd, J. H.F., Briley-Saebo, K. C., Mani, V., Goldschlager, G., Machac, J., Fuster, V., Fayad, Z. A.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.166173</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Detection of Neovessels in Atherosclerotic Plaques of Rabbits Using Dynamic Contrast Enhanced MRI and 18F-FDG PET]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1317</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1311</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1318?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Recombinant Activated Protein C Attenuates Endothelial Injury and Inhibits Procoagulant Microparticles Release in Baboon Heatstroke]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1318?rss=1</link>
<description><![CDATA[
<p><b><I>Objectives&mdash;</I></b> We tested the hypothesis that the antithrombotic and cytoprotective effects of recombinant human activated protein C (rhAPC) protect baboons against the lethal effects of heatstroke.</p>
<p><b><I>Methods and Results&mdash;</I></b> Fourteen anesthetized baboons assigned randomly to rhAPC (n=7) or control group (n=7) were heat-stressed in a prewarmed incubator at 44 to 47&deg;C until systolic blood pressure fell below 90 mm Hg, which signaled severe heatstroke. rhAPC was administered intravenously (24 &micro;g/kg/h) for 12 hours at onset of heatstroke. Heat stress induced coagulation and fibrinolysis activation as evidenced by a significant increase from baseline levels in plasma levels of thrombin-antithrombin (TAT) complexes, tissue plasminogen activator, and D-dimer. Heat stress elicited cell activation/injury as assessed by the release of interleukin (IL)-6, soluble thrombomodulin, and procoagulant microparticles (MPs). rhAPC did not significantly reduce heatstroke-induced thrombin generation, and D-dimer and had no effect on fibrinolytic activity. In contrast, rhAPC infusion attenuated significantly the plasma rise of IL-6 and inhibited the release of soluble thrombomodulin and MPs as compared with control group. No difference in survival was observed between rhAPC-treated and control group.</p>
<p><b><I>Conclusions&mdash;</I></b> rhAPC given to heatstroke baboons provided cytoprotection, but had no effect on heatstroke-induced coagulation activation and fibrin formation. Inhibition of MPs by rhAPC suggested a novel mechanism of action for this protein.</p>
]]></description>
<dc:creator><![CDATA[Bouchama, A., Kunzelmann, C., Dehbi, M., Kwaasi, A., Eldali, A., Zobairi, F., Freyssinet, J.-M., de Prost, D.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.161737</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Recombinant Activated Protein C Attenuates Endothelial Injury and Inhibits Procoagulant Microparticles Release in Baboon Heatstroke]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1325</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1318</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1326?rss=1">
<title><![CDATA[[Cell Biology and Signaling] Platelet Protein Interactions: Map, Signaling Components, and Phosphorylation Groundstate]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1326?rss=1</link>
<description><![CDATA[
<p><b><I>Objectives&mdash;</I></b> Assembly of a comprehensive proteome and transcriptome database of human platelets, derivation of a model of the platelet-specific interactome, and generation of a functional interaction map of platelet phosphorylations and kinases.</p>
<p><b><I>Methods and Results&mdash;</I></b> Interactions are derived from literature-curated data from HPRD and yeast two hybrid (Y2H) and mapped to platelet-specific expression data (SAGE or proteome). From this a cell-type specific model of platelet proteins and protein&ndash;protein interactions is derived. The obtained inventory of platelet-specific proteins includes key domains, protein GO annotations, and receptors. Collected interactions point to new platelet signaling components, actin remodeling processes, and pharmacological targets and offer incentives for further studies (eg, on the IPP complex). Integration of platelet-specific phosphoproteins and the characterization of the platelet kinase repertoire sketch a first outline of kinase signaling in human platelets.</p>
<p><b><I>Conclusions&mdash;</I></b> A first view of the platelet interactome, platelet phosphorylation, and platelet kinome is available from the in silico data.</p>
]]></description>
<dc:creator><![CDATA[Dittrich, M., Birschmann, I., Mietner, S., Sickmann, A., Walter, U., Dandekar, T.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.161000</dc:identifier>
<dc:title><![CDATA[[Cell Biology and Signaling] Platelet Protein Interactions: Map, Signaling Components, and Phosphorylation Groundstate]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1331</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1326</prism:startingPage>
<prism:section>Cell Biology and Signaling</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1332?rss=1">
<title><![CDATA[[Cell Biology and Signaling] Intracellular Localization of Cthrc1 Characterizes Differentiated Smooth Muscle]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1332?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> We recently reported expression of collagen triple helix repeat containing-1 (Cthrc1) in injured arteries and proteolytic cleavage of Cthrc1 in smooth muscle cells in vitro. The present study characterizes Cthrc1 processing and determines its biological significance.</p>
<p><b><I>Methods and Results&mdash;</I></b> Domain-specific antibodies localized full-length Cthrc1 in the cytoplasm of vascular, gastrointestinal, and uterine smooth muscle as well as in some neurons. Unlike smooth muscle -actin, Cthrc1 was not expressed in the embryonic myocardium. Intracellular localization of full-length Cthrc1 was sharply reduced in dedifferentiated smooth muscle of the developing neointima despite the previously shown increase in mRNA levels with accompanying extracellular Cthrc1 immunoreactivity. Immunoblotting suggested an apparent covalent association of monomeric full-length Cthrc1 with a cytoplasmic protein present in differentiated smooth muscle. Plasmin was identified as a protease that cleaved a putative propeptide generating an N-terminally truncated form of Cthrc1 with increased inhibitory activity of procollagen synthesis.</p>
<p><b><I>Conclusions&mdash;</I></b> Our data show that the differentiated smooth muscle cell phenotype is associated with the intracellular localization of noncleaved Cthrc1 despite the presence of a signal peptide. On arterial injury, increased Cthrc1 expression with apparent extracellular localization of N-terminally truncated Cthrc1 occurs. Removal of the propeptide correlated with increased activity of the molecule.</p>
]]></description>
<dc:creator><![CDATA[LeClair, R. J., Wang, Q., Benson, M. A., Prudovsky, I., Lindner, V.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.166579</dc:identifier>
<dc:title><![CDATA[[Cell Biology and Signaling] Intracellular Localization of Cthrc1 Characterizes Differentiated Smooth Muscle]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1338</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1332</prism:startingPage>
<prism:section>Cell Biology and Signaling</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1339?rss=1">
<title><![CDATA[[Cell Biology and Signaling] KLF2 Primes the Antioxidant Transcription Factor Nrf2 for Activation in Endothelial Cells]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1339?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> Atheroprotective blood flow induces expression of anti-inflammatory Kr&uuml;ppel-like factor 2 (KLF2) and activates antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) in vascular endothelium. Previously, we obtained KLF2-induced gene expression profiles in ECs, containing several Nrf2 target genes. Our aim was to investigate the role of KLF2 in shear stress&ndash;mediated activation of Nrf2 in human umbilical vein endothelial cells (HUVECs).</p>
<p><b><I>Methods and Results&mdash;</I></b> Expression of Nrf2 and its targets NAD(P)H dehydrogenase quinone 1 (NQO1) and heme oxygenase (HO-1) was elevated by shear and KLF2. KLF2 knockdown showed that shear-induced expression of NQO1 but not Nrf2 was dependent on KLF2. KLF2 overexpression in absence of flow resulted in more efficient activation of Nrf2 by tert-butyl hydroquinone (tBHQ) through enhanced nuclear localization, and promoted expression of a large panel of Nrf2-dependent genes resulting in superior protection against oxidative stress. Comparison of shear-, KLF2-, and Nrf2-induced transcriptomes showed that the majority of shear-modulated gene sets is influenced by KLF2 or Nrf2.</p>
<p><b><I>Conclusions&mdash;</I></b> We report that KLF2 substantially enhances antioxidant activity of Nrf2 by increasing its nuclear localization and activation. The synergistic activity of these two transcription factors forms a major contribution to the shear stress&ndash;elicited transcriptome in endothelial cells.</p>
]]></description>
<dc:creator><![CDATA[Fledderus, J. O., Boon, R. A., Volger, O. L., Hurttila, H., Yla-Herttuala, S., Pannekoek, H., Levonen, A.-L., Horrevoets, A. J.G.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165811</dc:identifier>
<dc:title><![CDATA[[Cell Biology and Signaling] KLF2 Primes the Antioxidant Transcription Factor Nrf2 for Activation in Endothelial Cells]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1346</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1339</prism:startingPage>
<prism:section>Cell Biology and Signaling</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1347?rss=1">
<title><![CDATA[[Cell Biology and Signaling] Nox4 and Nox2 NADPH Oxidases Mediate Distinct Cellular Redox Signaling Responses to Agonist Stimulation]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1347?rss=1</link>
<description><![CDATA[
<p><b><I>Objectives&mdash;</I></b> The NADPH oxidase isoforms Nox2 and Nox4 are coexpressed in many cell types and are implicated in agonist-stimulated redox-sensitive signal transduction. We compared the involvement of Nox2 versus Nox4 in redox-sensitive protein kinase activation after agonist stimulation.</p>
<p><b><I>Methods and Results&mdash;</I></b> We transfected HEK293 cells with Nox2 or Nox4 and compared ROS production and activation of mitogen activated protein kinases (MAPKs), Akt, and GSK3&beta; after acute agonist stimulation. Nox4 overexpression substantially increased basal ROS generation whereas ROS generation in response to angiotensin II and tumor necrosis factor (TNF) was enhanced in Nox2-overexpressing cells. Nox4 overexpression induced basal activation of ERK1/2 and JNK whereas Nox2-transfected cells showed a modest increase in p38MAPK activation. After angiotensin II or TNF treatment, JNK activation was augmented in Nox2 but not Nox4-transfected cells, whereas insulin augmented phosphorylation of p38MAPK, Akt, and GSK3&beta; specifically in Nox4-overexpressing cells and JNK specifically in Nox2-overexpressing cells.</p>
<p><b><I>Conclusions&mdash;</I></b> These data indicate that Nox2 and Nox4 exhibit distinctive patterns of acute activation by angiotensin II, TNF, and insulin and regulate the activation of distinct protein kinases.</p>
]]></description>
<dc:creator><![CDATA[Anilkumar, N., Weber, R., Zhang, M., Brewer, A., Shah, A. M.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.164277</dc:identifier>
<dc:title><![CDATA[[Cell Biology and Signaling] Nox4 and Nox2 NADPH Oxidases Mediate Distinct Cellular Redox Signaling Responses to Agonist Stimulation]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1354</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1347</prism:startingPage>
<prism:section>Cell Biology and Signaling</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1355?rss=1">
<title><![CDATA[[Cell Biology and Signaling] TRIB3 R84 Variant Is Associated With Impaired Insulin-Mediated Nitric Oxide Production in Human Endothelial Cells]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1355?rss=1</link>
<description><![CDATA[
<p><b><I>Background&mdash;</I></b> In the endothelium, insulin promotes nitric oxide (NO) production, through the insulin receptor/IRS-1/PI3-Kinase/Akt/eNOS signaling pathway. An inhibitor of insulin action, TRIB3, has recently been identified which affects insulin action by binding to and inhibiting Akt phosphorylation. We have recently described a Q84R gain-of-function polymorphism of <I>TRIB3</I> with the R84 variant being associated with insulin resistance and an earlier age at myocardial infarction.</p>
<p><b><I>Methods and Results&mdash;</I></b> To investigate the <I>TRIB3</I> R84 variant impact on endothelial insulin action, we cultured human umbilical vein endothelial cells (HUVECs) naturally carrying different <I>TRIB3</I> genotypes (QQ-, QR-, or RR-HUVECs). TRIB3 inhibitory activity on insulin-stimulated Akt phosphorylation and the amount of protein which was coimmunoprecipitable with Akt were significantly greater in QR- and RR- as compared to QQ- HUVECs. After insulin stimulation, Akt and eNOS activation as well as NO production were markedly decreased in QR- and RR- as compared to QQ-HUVECs. TRIB3 molecular modeling analysis provided insights into the structural changes related to the polymorphisms potentially determining differences in protein-protein interaction with Akt.</p>
<p><b><I>Conclusions&mdash;</I></b> Our data demonstrate that the <I>TRIB3</I> R84 variant impairs insulin signaling and NO production in human endothelial cells. This finding provides a plausible biological background for the deleterious role of <I>TRIB3</I> R84 on genetic susceptibility to coronary artery disease.</p>
]]></description>
<dc:creator><![CDATA[Andreozzi, F., Formoso, G., Prudente, S., Hribal, M. L., Pandolfi, A., Bellacchio, E., Di Silvestre, S., Trischitta, V., Consoli, A., Sesti, G.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:subject><![CDATA[Genetics of cardiovascular disease, Endothelium/vascular type/nitric oxide]]></dc:subject>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.162883</dc:identifier>
<dc:title><![CDATA[[Cell Biology and Signaling] TRIB3 R84 Variant Is Associated With Impaired Insulin-Mediated Nitric Oxide Production in Human Endothelial Cells]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1360</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1355</prism:startingPage>
<prism:section>Cell Biology and Signaling</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1361?rss=1">
<title><![CDATA[[Cell Biology and Signaling] Urokinase Plasminogen Activator Upregulates Paraoxonase 2 Expression in Macrophages Via an NADPH Oxidase-Dependent Mechanism]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1361?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> Macrophage foam cells are characterized by increased oxidative stress. Macrophage urokinase plasminogen activator (uPA) was shown to contribute to atherosclerosis progression. We hypothesized that uPA atherogenicity is related to its ability to increase macrophage oxidative stress. Increased macrophage oxidative stress in turn was shown to enhance PON2 expression. In the present study we investigated the effect of uPA on macrophage PON2 expression in relation to cellular oxidative stress.</p>
<p><b><I>Methods and Results&mdash;</I></b> uPA increased PON2 expression in THP-1 macrophages in a dose-dependent manner. This effect required uPA/uPAR interaction and was abolished by cell treatment with antioxidants. uPA increased macrophage oxidative stress, measured by increased lipid peroxides, reactive oxygen species formation, superoxide anion release, and cell-mediated LDL oxidation. These effects were related to uPA-mediated activation of NADPH oxidase, and could not be reproduced in mouse peritoneal macrophages (MPM) harvested from p47<sup><I>phox</I></sup>&ndash;/&ndash; mice, suggesting a causal relationship between NADPH oxidase activation and the effects of uPA on macrophage oxidative stress and PON2 expression. Finally, MPM from PON2<sup>&ndash;/&ndash;</sup> mice were more susceptible to uPA-induced cellular oxidative stress than wild-type MPM, suggesting that PON2 protects against uPA-stimulated macrophage oxidative stress.</p>
<p><b><I>Conclusions&mdash;</I></b> Upregulation of macrophage PON2 may provide a compensatory protective mechanism against uPA-stimulation of macrophage oxidative stress during atherogenesis.</p>
]]></description>
<dc:creator><![CDATA[Fuhrman, B., Khateeb, J., Shiner, M., Nitzan, O., Karry, R., Volkova, N., Aviram, M.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.166041</dc:identifier>
<dc:title><![CDATA[[Cell Biology and Signaling] Urokinase Plasminogen Activator Upregulates Paraoxonase 2 Expression in Macrophages Via an NADPH Oxidase-Dependent Mechanism]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1367</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1361</prism:startingPage>
<prism:section>Cell Biology and Signaling</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1368?rss=1">
<title><![CDATA[[Cell Biology and Signaling] Adiponectin Decreases C-Reactive Protein Synthesis and Secretion From Endothelial Cells: Evidence for an Adipose Tissue-Vascular Loop]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1368?rss=1</link>
<description><![CDATA[
<p><b><I>Background and Objective&mdash;</I></b> Inflammation is pivotal in atherosclerosis. C-reactive protein (CRP), in addition to being a cardiovascular risk marker, may also be proatherogenic. We have previously shown that in addition to the liver, human aortic endothelial cells (HAECs) synthesize and secrete CRP. Whereas CRP levels are increased in obesity, metabolic syndrome, and diabetes, levels of adiponectin are reduced in these conditions. We tested the hypothesis that adiponectin reduces CRP synthesis and secretion in HAECs under normoglycemic (5.5 mmol/L glucose) and hyperglycemic conditions (15 mmol/L glucose).</p>
<p><b><I>Methods and Results&mdash;</I></b> Adiponectin dose-dependently reduced CRP mRNA and protein from HAECs. Adiponectin treatment of HAECs significantly decreased IB phosphorylation and NFB binding activity. There was no effect of adiponectin on STAT or C/EBP transcriptional activity. Adiponectin also activated AMP kinase resulting in decreased NFB activity and decreased CRP mRNA and protein. These effects of adiponectin were mimicked by AICAR, an activator of AMPK, and reversed by inhibition of AMPK. Thus, adiponectin reduces CRP synthesis and secretion from HAECs under hyperglycemia via upregulation of AMP kinase and downregulation of NFB. Similar findings were observed in rat primary hepatocytes.</p>
<p><b><I>Conclusions&mdash;</I></b> Thus, in obesity and diabetes, the hypoadiponectinemia could exacerbate the proinflammatory state by inducing CRP production.</p>
]]></description>
<dc:creator><![CDATA[Devaraj, S., Torok, N., Dasu, M. R., Samols, D., Jialal, I.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.163303</dc:identifier>
<dc:title><![CDATA[[Cell Biology and Signaling] Adiponectin Decreases C-Reactive Protein Synthesis and Secretion From Endothelial Cells: Evidence for an Adipose Tissue-Vascular Loop]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1374</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1368</prism:startingPage>
<prism:section>Cell Biology and Signaling</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1375?rss=1">
<title><![CDATA[[Cell Biology and Signaling] Complete Downmodulation of P-Selectin Glycoprotein Ligand in Monocytes Undergoing Apoptosis]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1375?rss=1</link>
<description><![CDATA[
<p><b><I>Objectives&mdash;</I></b> Apoptotic monocytes release membrane microparticles which may play a major role in thrombogenicity through a P-selectin glycoprotein ligand (PGSL-1)&ndash;mediated mechanism. We have studied systematically the regulation of PSGL-1 expression and function in apoptotic monocytic cells.</p>
<p><b><I>Methods and Results&mdash;</I></b> PSGL-1 expression (flow cytometry, immunofluorescence microscopy, immunoblot) was virtually abolished in apoptotic monocytes by proteolytic shedding. This was accompanied by a complete loss of PSGL-1&ndash;mediated platelet&ndash;leukocyte (flow cytometry) and leukocyte&ndash;endothelial cell (parallel plate flow chamber) interactions. Systematic screening of protease inhibitors combined with knock-out and siRNA experiments characterized the PSGL-1-cleaving enzyme as an N-ethylmaleimide-inhibitable metalloproteinase of the ADAM family.</p>
<p><b><I>Conclusions&mdash;</I></b> Downmodulation of PGSL-1 in apoptotic monocytes may prevent ectopic cell clearance in the peripheral vasculature to reduce local inflammatory and proliferative responses. Depletion of PSGL-1 expression on apoptotic microparticles may also act as a molecular switch to modulate their thrombogenic activity.</p>
]]></description>
<dc:creator><![CDATA[Stampfuss, J.-J., Censarek, P., Fischer, J. W., Kaber, G., Rauch, B. H., Freidel, K., Fischer, U., Schulze-Osthoff, K., Grosser, T., Grandoch, M., Schror, K., Weber, A.-A.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.166629</dc:identifier>
<dc:title><![CDATA[[Cell Biology and Signaling] Complete Downmodulation of P-Selectin Glycoprotein Ligand in Monocytes Undergoing Apoptosis]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1378</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1375</prism:startingPage>
<prism:section>Cell Biology and Signaling</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1379?rss=1">
<title><![CDATA[[Clinical and Population Studies] Prognostic Value of Leukocyte Telomere Length in Patients With Stable Coronary Artery Disease: Data From the Heart and Soul Study]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1379?rss=1</link>
<description><![CDATA[
<p><b><I>Background&mdash;</I></b> Telomere shortening has been proposed as a marker of biological aging. Whether leukocyte telomere length is associated with mortality among patients with stable coronary artery disease (CAD) is unknown.</p>
<p><b><I>Methods and Results&mdash;</I></b> We measured leukocyte telomere length in 780 patients with stable CAD in a prospective cohort study. Participants were categorized by quartiles of telomere length. Hazard Ratios (HRs) and 95% confidence intervals were calculated for all-cause mortality, heart failure (HF) hospitalization, and cardiovascular (CV) events. After 4.4 years of follow-up there were 166 deaths. Compared with participants in the highest telomere length quartile, those in the lowest quartile were at increased risk of death (age-adjusted HR 1.8; 95% CI 1.2 to 2.9). After multivariate adjustment for clinical (HR 2.1; CI 1.3 to 3.3), inflammatory (HR 2.0; CI 1.2 to 3.2), and echocardiographic (HR 1.9; CI 1.0 to 3.5) risk factors, patients in the lowest quartile of telomere length remained at significantly increased risk of death compared to those in the highest quartile. Patients in the lowest quartile of telomere length were also at significantly increased risk of HF hospitalization (HR 2.6; CI 1.1 to 6.0) but not CV events (HR 1.7; CI 0.9 to 3.5).</p>
<p><b><I>Conclusions&mdash;</I></b> Reduced leukocyte telomere length is associated with all-cause mortality in patients with stable CAD. The prognostic value of short telomeres in predicting death is not completely captured by existing clinical, inflammatory, and echocardiographic markers of risk.</p>
]]></description>
<dc:creator><![CDATA[Farzaneh-Far, R., Cawthon, R. M., Na, B., Browner, W. S., Schiller, N. B., Whooley, M. A.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.167049</dc:identifier>
<dc:title><![CDATA[[Clinical and Population Studies] Prognostic Value of Leukocyte Telomere Length in Patients With Stable Coronary Artery Disease: Data From the Heart and Soul Study]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1384</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1379</prism:startingPage>
<prism:section>Clinical and Population Studies</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1385?rss=1">
<title><![CDATA[[Clinical and Population Studies] High-Sensitivity C-Reactive Protein and Coronary Heart Disease in a General Population of Japanese: The Hisayama Study]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1385?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> The purpose of this study was to investigate the effects of high-sensitivity C-reactive protein (hs-CRP) on the risks of coronary heart disease (CHD) in a general population of Japanese.</p>
<p><b><I>Methods and Results&mdash;</I></b> The Hisayama study is a population-based prospective cohort study. A total of 2589 participants aged 40 years or older were followed up for 14 years. Outcomes are incident CHD (myocardial infarction, coronary revascularization, and sudden cardiac death). The median hs-CRP level was 0.43 mg/L at baseline. During the follow-up period, 129 coronary events were observed. Age- and sex-adjusted annual incidence rates of CHD rose progressively with higher hs-CRP levels: 1.6, 3.3, 4.5, and 7.4 per 1000 person-years for quartile groups defined by hs-CRP levels of &lt;0.21, 0.21 to 0.43, 0.44 to 1.02, and &gt;1.02 mg/L, respectively (<I>P</I>&lt;0.0001 for trend). The risk of CHD in the highest quartile group was 2.98-fold (95% CI, 1.53 to 5.82) higher than that in the lowest group even after controlling for other cardiovascular risk factors.</p>
<p><b><I>Conclusions&mdash;</I></b> hs-CRP levels were clearly associated with future CHD events in a general population of Japanese. In Japanese populations, the hs-CRP cut-off point for high-risk of future development of CHD is likely to be &gt;1.0 mg/L, which is much lower than that for Western populations.</p>
]]></description>
<dc:creator><![CDATA[Arima, H., Kubo, M., Yonemoto, K., Doi, Y., Ninomiya, T., Tanizaki, Y., Hata, J., Matsumura, K., Iida, M., Kiyohara, Y.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:subject><![CDATA[Cerebrovascular disease/stroke, Risk Factors, Acute myocardial infarction, Epidemiology]]></dc:subject>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.157164</dc:identifier>
<dc:title><![CDATA[[Clinical and Population Studies] High-Sensitivity C-Reactive Protein and Coronary Heart Disease in a General Population of Japanese: The Hisayama Study]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1391</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1385</prism:startingPage>
<prism:section>Clinical and Population Studies</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1392?rss=1">
<title><![CDATA[[Clinical and Population Studies] Distension of the Carotid Artery and Risk of Coronary Events: The Three-City Study]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1392?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> Arterial mechanical properties are of growing interest in the understanding of cardiovascular disease development. We aimed to determine the predictive value of carotid wall mechanics on coronary heart disease (CHD) in the Three-City study.</p>
<p><b><I>Methods and Results&mdash;</I></b> At baseline, 3337 participants aged &ge;65 years underwent a carotid B-mode ultrasonography. During a median follow-up of 43.4 months, 128 CHD occurred. Increased carotid distension (relative stroke change in lumen diameter) was significantly associated with CHD risk. Comparison of subjects in tertile 3 versus those in tertile 1 (reference) showed a hazard ratio (HR) of 1.80 (95% CI, 1.17 to 2.75). Controlling for various confounders including age, heart rate, brachial (or carotid) pulse pressure, and common carotid intima-media thickness did not alter the association between carotid distension and CHD with a HR of 1.79 (95% CI, 1.12 to 2.86; tertile 3 versus tertile 1). Brachial and carotid pulse pressures were also independently associated with CHD. No association was found between CHD and carotid distensibility coefficient, cross-sectional compliance coefficient, Young&rsquo;s elastic modulus, or &beta; stiffness index.</p>
<p><b><I>Conclusions&mdash;</I></b> In the elderly, increased carotid distension was independently predictive of CHD. This simple and noninvasive parameter might be of particular interest for cardiovascular risk assessment.</p>
]]></description>
<dc:creator><![CDATA[Leone, N., Ducimetiere, P., Gariepy, J., Courbon, D., Tzourio, C., Dartigues, J.-F., Ritchie, K., Alperovitch, A., Amouyel, P., Safar, M. E., Zureik, M.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:subject><![CDATA[Remodeling, Other arteriosclerosis, Imaging, Acute coronary syndromes, Epidemiology]]></dc:subject>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.164582</dc:identifier>
<dc:title><![CDATA[[Clinical and Population Studies] Distension of the Carotid Artery and Risk of Coronary Events: The Three-City Study]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1397</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1392</prism:startingPage>
<prism:section>Clinical and Population Studies</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1398?rss=1">
<title><![CDATA[[Clinical and Population Studies] Do Psychological Factors Affect Inflammation and Incident Coronary Heart Disease: The Whitehall II Study]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1398?rss=1</link>
<description><![CDATA[
<p><b><I>Objectives&mdash;</I></b> The purpose of this study was to test whether psychological factors affect inflammation processes to an extent that increases the risk of coronary heart disease (CHD).</p>
<p><b><I>Methods and Results&mdash;</I></b> We used data from 6396 civil servants (4453 men, 1943 women) from the Whitehall II Study, aged 35 to 55 years and free from clinically validated CHD at the start of the follow-up period. Two psychological factors were assessed at phase 1 (1985 to 1988) and phase 2 (1989 to 1990): negative affect and psychological distress. Inflammatory biomarkers (fibrinogen, high-sensitivity C-reactive- protein, interleukin-6) and 12 baseline covariates including biological and behavioral CHD risk factors, sociodemographic variables, and work stress were measured at phase 3 (1991 to 1993). Follow-up for CHD death, first nonfatal myocardial infarction, or definite angina occurring between phase 3 and phase 7 (2003 to 2004) was based on clinical records. Higher levels of inflammatory markers were associated with higher CHD incidence, with hazard ratios (HR) ranging from 1.31 to 2.37 in age-and sex-adjusted models. Higher levels of negative affectivity and psychological distress were not associated with greater concentrations of inflammatory markers. Negative affectivity (relative index of inequality=1.68, 95% confidence interval [CI] 1.20 to 2.36) and higher psychological distress exposure (HR=1.66, 95% CI 1.28 to 2.14) were associated with higher CHD incidence and these associations remained unchanged after adjustment for inflammatory markers.</p>
<p><b><I>Conclusions&mdash;</I></b> Our findings suggest that psychological factors do not affect inflammation although they predict incident CHD.</p>
]]></description>
<dc:creator><![CDATA[Nabi, H., Singh-Manoux, A., Shipley, M., Gimeno, D., Marmot, M. G., Kivimaki, M.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.167239</dc:identifier>
<dc:title><![CDATA[[Clinical and Population Studies] Do Psychological Factors Affect Inflammation and Incident Coronary Heart Disease: The Whitehall II Study]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1406</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1398</prism:startingPage>
<prism:section>Clinical and Population Studies</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/7/1407?rss=1">
<title><![CDATA[[Clinical and Population Studies] Polymorphisms of the IL1-Receptor Antagonist Gene (IL1RN) Are Associated With Multiple Markers of Systemic Inflammation]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/7/1407?rss=1</link>
<description><![CDATA[
<p><b><I>Background&mdash;</I></b> Circulating levels of acute phase reactant proteins such as plasma C-reactive protein (CRP) are likely influenced by multiple genes regulating the innate immune response.</p>
<p><b><I>Methods and Results&mdash;</I></b> We screened a set of 16 inflammation-related genes for association with CRP in a large population-based study of healthy young adults (n=1627). Results were validated in 2 independent studies (n=1208 and n=4310), including a pooled analysis of all 3 studies. In the pooled analysis, the minor allele of <I>IL1RN</I> 1018 (rs4251961) within the gene encoding interleukin (IL)-1 receptor antagonist (IL-1RA) was significantly associated with higher mean plasma log(CRP) level (<I>P</I>&lt;1<FONT FACE="arial,helvetica">x</FONT>10<sup>&ndash;4</sup>). The same <I>IL1RN</I> 1018 allele was associated with higher mean plasma log(IL-6) levels (<I>P</I>=0.004). In the pooled analysis, the minor allele of <I>IL1RN</I> 13888 (rs2232354) was associated with higher fibrinogen, (<I>P</I>=0.001). The <I>IL1RN</I> 1018 and 13888 variant alleles tag a clade of <I>IL1RN</I> haplotypes linked to allele 1 of an 86-bp VNTR polymorphism. We confirmed that the <I>IL1RN</I> 1018 variant (rs4251961) was associated with decreased cellular IL-1RA production ex vivo.</p>
<p><b><I>Conclusions&mdash;</I></b> Common functional polymorphisms of the <I>IL1RN</I> gene are associated with several markers of systemic inflammation.</p>
]]></description>
<dc:creator><![CDATA[Reiner, A. P., Wurfel, M. M., Lange, L. A., Carlson, C. S., Nord, A. S., Carty, C. L., Rieder, M. J., Desmarais, C., Jenny, N. S., Iribarren, C., Walston, J. D., Williams, O. D., Nickerson, D. A., Jarvik, G. P.]]></dc:creator>
<dc:date>2008-06-18</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.167437</dc:identifier>
<dc:title><![CDATA[[Clinical and Population Studies] Polymorphisms of the IL1-Receptor Antagonist Gene (IL1RN) Are Associated With Multiple Markers of Systemic Inflammation]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1412</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>1407</prism:startingPage>
<prism:section>Clinical and Population Studies</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/e32?rss=1">
<title><![CDATA[[Abstracts of the Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference 2008] 2008 ATVB Oral Presentations]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/e32?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/01.ATV.0000319737.80976.26</dc:identifier>
<dc:title><![CDATA[[Abstracts of the Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference 2008] 2008 ATVB Oral Presentations]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>e149</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>e32</prism:startingPage>
<prism:section>Abstracts of the Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference 2008</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/e150?rss=1">
<title><![CDATA[[Corrections] Correction]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/e150?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.654321</dc:identifier>
<dc:title><![CDATA[[Corrections] Correction]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>e150</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>e150</prism:startingPage>
<prism:section>Corrections</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1031?rss=1">
<title><![CDATA[[Editorials] The Homocysteine Paradox]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1031?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Rodionov, R. N., Lentz, S. R.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.164830</dc:identifier>
<dc:title><![CDATA[[Editorials] The Homocysteine Paradox]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1033</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1031</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1034?rss=1">
<title><![CDATA[[Editorials] "Priming" Endothelial Progenitor Cells: A New Strategy to Improve Cell Based Therapeutics]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1034?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Gurtner, G. C., Chang, E.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.163246</dc:identifier>
<dc:title><![CDATA[[Editorials] "Priming" Endothelial Progenitor Cells: A New Strategy to Improve Cell Based Therapeutics]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1035</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1034</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1036?rss=1">
<title><![CDATA[[Editorials] Preventing Stenosis by Local Inhibition of KCa3.1: A Finger on the Phenotypic Switch]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1036?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Lounsbury, K. M.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.164988</dc:identifier>
<dc:title><![CDATA[[Editorials] Preventing Stenosis by Local Inhibition of KCa3.1: A Finger on the Phenotypic Switch]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1038</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1036</prism:startingPage>
<prism:section>Editorials</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1039?rss=1">
<title><![CDATA[[Brief Reviews] Abdominal Obesity and the Metabolic Syndrome: Contribution to Global Cardiometabolic Risk]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1039?rss=1</link>
<description><![CDATA[
<p>There is currently substantial confusion between the conceptual definition of the metabolic syndrome and the clinical screening parameters and cut-off values proposed by various organizations (NCEP-ATP III, IDF, WHO, etc) to identify individuals with the metabolic syndrome. Although it is clear that in vivo insulin resistance is a key abnormality associated with an atherogenic, prothrombotic, and inflammatory profile which has been named by some the "metabolic syndrome" or by others "syndrome X" or "insulin resistance syndrome", it is more and more recognized that the most prevalent form of this constellation of metabolic abnormalities linked to insulin resistance is found in patients with abdominal obesity, especially with an excess of intra-abdominal or visceral adipose tissue. We have previously proposed that visceral obesity may represent a clinical intermediate phenotype reflecting the relative inability of subcutaneous adipose tissue to act as a protective metabolic sink for the clearance and storage of the extra energy derived from dietary triglycerides, leading to ectopic fat deposition in visceral adipose depots, skeletal muscle, liver, heart, etc. Thus, visceral obesity may partly be a marker of a dysmetabolic state and partly a cause of the metabolic syndrome. Although waist circumference is a better marker of abdominal fat accumulation than the body mass index, an elevated waistline alone is not sufficient to diagnose visceral obesity and we have proposed that an elevated fasting triglyceride concentration could represent, when waist circumference is increased, a simple clinical marker of excess visceral/ectopic fat. Finally, a clinical diagnosis of visceral obesity, insulin resistance, or of the metabolic syndrome is not sufficient to assess global risk of cardiovascular disease. To achieve this goal, physicians should first pay attention to the classical risk factors while also considering the additional risk resulting from the presence of abdominal obesity and the metabolic syndrome, such global risk being defined as cardiometabolic risk.</p>
]]></description>
<dc:creator><![CDATA[Despres, J.-P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Rodes-Cabau, J., Bertrand, O. F., Poirier, P.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.159228</dc:identifier>
<dc:title><![CDATA[[Brief Reviews] Abdominal Obesity and the Metabolic Syndrome: Contribution to Global Cardiometabolic Risk]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1049</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1039</prism:startingPage>
<prism:section>Brief Reviews</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1050?rss=1">
<title><![CDATA[[Brief Reviews] Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1050?rss=1</link>
<description><![CDATA[
<p>Peroxisome proliferator-activated receptors (PPARs) and (liver X receptors) LXRs are ligand-activated transcription factors that control lipid and glucose metabolism, as well as the inflammatory response. Because the macrophage plays an important role in host defense and immunoinflammatory pathologies, particular attention has been paid to the role of PPARs and LXRs in the control of macrophage gene expression and function. Research over the last few years has revealed important roles for PPAR-, PPAR-, and LXRs in macrophage inflammation and cholesterol homeostasis with consequences for atherosclerosis development. In this review we will discuss the role of these transcription factors in the control of macrophage activities, with particular attention to species-differences in macrophage function control by PPARs and LXR between rodents and humans.</p>
]]></description>
<dc:creator><![CDATA[Rigamonti, E., Chinetti-Gbaguidi, G., Staels, B.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.158998</dc:identifier>
<dc:title><![CDATA[[Brief Reviews] Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1059</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1050</prism:startingPage>
<prism:section>Brief Reviews</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1060?rss=1">
<title><![CDATA[[Brief Reviews] Regulation of Endogenous Apolipoprotein E Secretion by Macrophages]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1060?rss=1</link>
<description><![CDATA[
<p>Apolipoprotein E has critical roles in the protection against atherosclerosis and is understood to follow the classical constitutive secretion pathway. Recent studies have indicated that the secretion of apoE from macrophages is a regulated process of unexpected complexity. Cholesterol acceptors such as apolipoprotein A-I, high density lipoprotein, and phospholipid vesicles can stimulate apoE secretion. The ATP binding cassette transporter ABCA1 is involved in basal apoE secretion and in lipidating apoE-containing particles secreted by macrophages. However, the stimulation of apoE secretion by apoA-I is ABCA1-independent, indicating the existence of both ABCA1-dependent and -independent pathways of apoE secretion. The release of apoE under basal conditions is also regulated, requiring intact protein kinase A activity, intracellular calcium, and an intact microtubular network. Mathematical modeling of apoE turnover indicates that whereas some pools of apoE are committed to either secretion or degradation, other pools can be diverted from degradation toward secretion. Targeted inhibition or stimulation of specific apoE trafficking pathways will provide unique opportunities to regulate the biology of this important molecule.</p>
]]></description>
<dc:creator><![CDATA[Kockx, M., Jessup, W., Kritharides, L.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:subject><![CDATA[Pathophysiology, Cell biology/structural biology, Cell signalling/signal transduction, Lipid and lipoprotein metabolism, Mechanism of atherosclerosis/growth factors]]></dc:subject>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.164350</dc:identifier>
<dc:title><![CDATA[[Brief Reviews] Regulation of Endogenous Apolipoprotein E Secretion by Macrophages]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1067</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1060</prism:startingPage>
<prism:section>Brief Reviews</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1068?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Augmentation of Vascular Remodeling by Uncoupled Endothelial Nitric Oxide Synthase in a Mouse Model of Diabetes Mellitus]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1068?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> Diabetes mellitus is associated with increased oxidative stress, which induces oxidation of tetrahydrobiopterin (BH4) in vessel wall. Without enough BH4, eNOS is uncoupled to L-arginine and produces superoxide rather than NO. We examined the role of uncoupled eNOS in vascular remodeling in diabetes.</p>
<p><b><I>Methods and Results&mdash;</I></b> Diabetes mellitus was produced by streptozotocin in C57BL/6J mice. Under stable hyperglycemia, the common carotid artery was ligated, and neointimal formation was examined 4 weeks later. In diabetic mice, the neointimal area was dramatically augmented. This augmentation was associated with increased aortic superoxide formation, reduced aortic BH4/dihydrobiopterin (BH2) ratio, and decreased plasma nitrite and nitrate (NOx) levels compared with nondiabetic mice. Chronic BH4 treatment (10 mg/kg/d) reduced the neointimal area in association with suppressed superoxide production and inflammatory changes in vessels. BH4/BH2 ratio in vessel wall was preserved, and plasma NOx levels increased. Furthermore, in the presence of diabetes, overexpression of bovine eNOS resulted in augmentation of neointimal area, accompanied by increased superoxide production in the endothelium.</p>
<p><b><I>Conclusions&mdash;</I></b> In diabetes, increased oxidative stress by uncoupled NOSs, particularly eNOS, causes augmentation of vascular remodeling. These findings indicate restoration of eNOS coupling has an atheroprotective benefit in diabetes.</p>
]]></description>
<dc:creator><![CDATA[Sasaki, N., Yamashita, T., Takaya, T., Shinohara, M., Shiraki, R., Takeda, M., Emoto, N., Fukatsu, A., Hayashi, T., Ikemoto, K., Nomura, T., Yokoyama, M., Hirata, K.-i., Kawashima, S.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:subject><![CDATA[Endothelium/vascular type/nitric oxide]]></dc:subject>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.160754</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Augmentation of Vascular Remodeling by Uncoupled Endothelial Nitric Oxide Synthase in a Mouse Model of Diabetes Mellitus]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1076</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1068</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1077?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] CCN1 Knockdown Suppresses Neointimal Hyperplasia in a Rat Artery Balloon Injury Model]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1077?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> CCN1 (Cyr61) is an extracellular matrix-associated protein involved in cell proliferation and survival. CCN1 is bound to vascular smooth muscle cells (VSMCs) via integrins and is expressed in VSMCs in atherosclerotic lesions, suggesting involvement in the regulation of vascular smooth muscle cell (VSMC) proliferation and atherosclerosis. We hypothesized that knockdown of CCN1 may inhibit VSMC proliferation and suppress neointimal hyperplasia.</p>
<p><b><I>Methods and Results&mdash;</I></b> We examined the effect of the knockdown of CCN1 using rat cultured VSMCs and a rat balloon injury model. CCN1 stimulated adhesion and migration of VSMCs in a dose-dependent manner, and this was blocked by an antibody for integrin <SUB>6</SUB>&beta;<SUB>1</SUB>. Moreover, knockdown of endogenous CCN1 by lentiviral delivery of siRNA significantly inhibited proliferation of VSMCs and the uptake of 5-bromo-2'-deoxyuridine (BrdU). Replenishment with recombinant CCN1 reversed the effect of siRNA knockdown. Interestingly, knockdown of CCN1 significantly suppressed neointimal hyperplasia in a rat carotid artery balloon injury model at days 14 and 28 after injury. Gene transfer of CCN1 to smooth muscle reversed the effect of CCN1 knockdown on neointimal formation. These results suggest that endogenous CCN1 regulates proliferation of VSMCs and neointimal hyperplasia.</p>
<p><b><I>Conclusion&mdash;</I></b> Inhibition of CCN1 may provide a promising strategy for the prevention of restenosis after vascular interventions.</p>
]]></description>
<dc:creator><![CDATA[Matsumae, H., Yoshida, Y., Ono, K., Togi, K., Inoue, K., Furukawa, Y., Nakashima, Y., Kojima, Y., Nobuyoshi, M., Kita, T., Tanaka, M.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.162362</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] CCN1 Knockdown Suppresses Neointimal Hyperplasia in a Rat Artery Balloon Injury Model]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1083</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1077</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1084?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Local Delivery of the KCa3.1 Blocker, TRAM-34, Prevents Acute Angioplasty-Induced Coronary Smooth Muscle Phenotypic Modulation and Limits Stenosis]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1084?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> We previously demonstrated that upregulation of intermediate-conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channels (K<SUB>Ca</SUB>3.1) is necessary for mitogen-induced phenotypic modulation in isolated porcine coronary smooth muscle cells (SMCs). The objective of the present study was to determine the role of K<SUB>Ca</SUB>3.1 in the regulation of coronary SMC phenotypic modulation in vivo using a swine model of postangioplasty restenosis.</p>
<p><b><I>Methods and Results&mdash;</I></b> Balloon angioplasty was performed on coronary arteries of swine using either noncoated or balloons coated with the specific K<SUB>Ca</SUB>3.1 blocker TRAM-34. Expression of K<SUB>Ca</SUB>3.1, c-jun, c-fos, repressor element-1 silencing transcription factor (REST), smooth muscle myosin heavy chain (SMMHC), and myocardin was measured using qRT-PCR in isolated medial cells 2 hours and 2 days postangioplasty. K<SUB>Ca</SUB>3.1, c-jun, and c-fos mRNA levels were increased 2 hours postangioplasty, whereas REST expression decreased. SMMHC expression was unchanged at 2 hours, but decreased 2 days postangioplasty. Use of TRAM-34 coated balloons prevented K<SUB>Ca</SUB>3.1 upregulation and REST downregulation at 2 hours, SMMHC and myocardin downregulation at 2 days, and attenuated subsequent restenosis 14 and 28 days postangioplasty. Immunohistochemical analysis demonstrated corresponding changes at the protein level.</p>
<p><b><I>Conclusion&mdash;</I></b> Blockade of K<SUB>Ca</SUB>3.1 by delivery of TRAM-34 via balloon catheter prevented smooth muscle phenotypic modulation and limited subsequent restenosis.</p>
]]></description>
<dc:creator><![CDATA[Tharp, D.L., Wamhoff, B.R., Wulff, H., Raman, G., Cheong, A., Bowles, D.K.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:subject><![CDATA[Restenosis, Ion channels/membrane transport, Smooth muscle proliferation and differentiation, Catheter-based coronary and valvular interventions: other]]></dc:subject>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.155796</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Local Delivery of the KCa3.1 Blocker, TRAM-34, Prevents Acute Angioplasty-Induced Coronary Smooth Muscle Phenotypic Modulation and Limits Stenosis]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1089</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1084</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1090?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1090?rss=1</link>
<description><![CDATA[
<p><b><I>Background&mdash;</I></b> Atherosclerosis is a chronic inflammatory disease that represents the primary cause of death through coronary disease and stroke. Chemokines are known to play a crucial role in this disease by recruiting inflammatory leukocytes to the endothelium. Recently, the chemokine variant [<sup>44</sup>AANA<sup>47</sup>]-RANTES was shown to impair inflammatory cell recruitment in vivo by interfering with heparin binding and oligomerization.</p>
<p><b><I>Methods and Results&mdash;</I></b> In this study we report that curative treatment with [<sup>44</sup>AANA<sup>47</sup>]-RANTES limits atherosclerotic plaque formation in LDLr<sup>&ndash;/&ndash;</sup> mice. This was associated with reduced infiltration of T cells and macrophages and reduced production of matrix metalloproteinase (MMP)-9. By contrast, the relative smooth muscle cell and collagen content was increased, indicating a more stable plaque phenotype. In addition, we provide evidence for direct inhibition of leukocyte recruitment into aortic root lesions, attenuated leukocyte rolling and arrest in mesenteric vessels, as well as a reduced proinflammatory response following Con A stimulation in vitro.</p>
<p><b><I>Conclusions&mdash;</I></b> Interference with chemokine oligomerization and chemokine/heparin interactions is a powerful novel approach that inhibits progression of established atherosclerosis in mice. By inhibiting leukocyte recruitment into plaques, [<sup>44</sup>AANA<sup>47</sup>]-RANTES mediates a less inflammatory plaque phenotype and thus reduced systemic inflammatory state.</p>
]]></description>
<dc:creator><![CDATA[Braunersreuther, V., Steffens, S., Arnaud, C., Pelli, G., Burger, F., Proudfoot, A., Mach, F.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165423</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1096</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1090</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1097?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Increased ADAM17 mRNA Expression and Activity Is Associated With Atherosclerosis Resistance in LDL-Receptor Deficient Mice]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1097?rss=1</link>
<description><![CDATA[
<p><b><I>Background&mdash;</I></b> We have previously identified an atherosclerosis quantitative trait locus (QTL) on mouse chromosome (Chr) 12 in an F2-intercross of atherosclerosis-resistant FVB and atherosclerosis-susceptible C57BL/6 (B6) mice on the LDL-receptor deficient (LDL<sup>&ndash;/&ndash;</sup>) background. The aim of the present study was to identify potentially causative genes at this locus.</p>
<p><b><I>Methods and Results&mdash;</I></b> Expression QTL (eQTL) analysis of candidate genes in livers of F2-mice revealed that <I>a disintegrin and metalloproteinase 17 (ADAM17</I>) mRNA expression mapped to the physical position of <I>ADAM17</I> on proximal Chr12 (21.6 Mb, LOD 3.3) and colocalized with the atherosclerosis QTL. The FVB allele was associated with significantly higher <I>ADAM17</I> mRNA expression (39%) than the B6 allele. Likewise, <I>ADAM17</I> mRNA levels in the parental strains were significantly elevated in FVB.LDLR<sup>&ndash;/&ndash;</sup> compared to B6.LDLR<sup>&ndash;/&ndash;</sup> mice in liver, macrophages, and aorta (68%, 58%, and 32%, respectively). Reporter gene assays revealed a genetic variant that might explain these expression differences. Moreover, FVB.LDLR<sup>&ndash;/&ndash;</sup> macrophages showed 5-fold increased PMA-induced shedding of tumor necrosis factor (TNF)- and 32% increased release of TNF-receptor I compared to B6.LDLR<sup>&ndash;/&ndash;</sup>. The atherosclerosis locus and expression differences were confirmed in Chr12 interval-specific congenic mice.</p>
<p><b><I>Conclusion&mdash;</I></b> Our data provide functional evidence for ADAM17 as a candidate gene of atherosclerosis susceptibility at the murine Chr12 QTL.</p>
]]></description>
<dc:creator><![CDATA[Holdt, L. M., Thiery, J., Breslow, J. L., Teupser, D.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165654</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Increased ADAM17 mRNA Expression and Activity Is Associated With Atherosclerosis Resistance in LDL-Receptor Deficient Mice]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1103</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1097</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1104?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Human LDL Receptor Enhances Sequestration of ApoE4 and VLDL Remnants on the Surface of Hepatocytes but Not Their Internalization in Mice]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1104?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> In humans, apolipoprotein (apo) E4 is associated with elevated plasma cholesterol levels and a high risk of developing atherosclerosis, whereas apoE2 is protective. Here we investigate the mechanism by which mice expressing human apoE isoforms recapitulate this association when they also express high levels of human low-density lipoprotein receptor (LDLR).</p>
<p><b><I>Methods and Results&mdash;</I></b> Primary hepatocytes from apoE4 mice secreted less apoE into the medium than hepatocytes from apoE2 mice. Increased LDLR expression decreased this secretion and increased degradation of apoE4. An apoE4-GFP fusion protein expressed in the liver of apoE-deficient mice accumulated on the hepatocyte surface bordering the space of Disse in an LDLR-dependent manner. Fluorescence-labeled very low&ndash;density lipoprotein (VLDL) remnants accumulated on the hepatocyte surface in apoE4 mice with high LDLR, but they were internalized poorly. In contrast, apoE2-GFP did not accumulate on the hepatocyte surface even when the LDLR expression was high, but apoE2 mice with high LDLR internalized the remnants avidly without sequestering them on the hepatocyte surface.</p>
<p><b><I>Conclusions&mdash;</I></b> The high affinity of apoE4 to the LDLR enhances VLDL sequestration on the hepatocyte surface but delays their internalization. This delay likely increases VLDL conversion to cholesterol-enriched remnants in apoE4 mice with high LDLR, and probably to LDL in humans with apoE4.</p>
]]></description>
<dc:creator><![CDATA[Altenburg, M., Arbones-Mainar, J., Johnson, L., Wilder, J., Maeda, N.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.164863</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Human LDL Receptor Enhances Sequestration of ApoE4 and VLDL Remnants on the Surface of Hepatocytes but Not Their Internalization in Mice]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1110</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1104</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1111?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Thrombocytopenia and Platelet Abnormalities in High-Density Lipoprotein Receptor-Deficient Mice]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1111?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> High-density lipoprotein (HDL) receptor, scavenger receptor class B, type I (SR-BI), mediated cellular uptake of lipoprotein cholesterol controls HDL structure and plasma HDL and biliary cholesterol levels. In SR-BI knockout (KO) mice, an unusually high plasma unesterified-to-total cholesterol ratio (UC:TC) and abnormally large HDL particles apparently contribute to pathology, including female infertility, susceptibility to atherosclerosis and coronary heart disease, and anemia. Here we examined the influence of SR-BI deficiency on platelets.</p>
<p><b><I>Methods and Results&mdash;</I></b> The high plasma UC:TC ratio in SR-BI KO mice was correlated with platelet abnormalities, including high cholesterol content, abnormal morphologies, high clearance rates, and thrombocytopenia. One day after platelets from wild-type mice were infused into SR-BI KO mice, they exhibited abnormally high cholesterol content and clearance rates similar to those of endogenous platelets. Platelets from SR-BI KO mice exhibited in vitro a blunted aggregation response to the agonist ADP but a normal response to PAR4.</p>
<p><b><I>Conclusions&mdash;</I></b> In SR-BI KO mice abnormal circulating lipoproteins, particularly their high UC:TC ratio&mdash;rather than the absence of SR-BI in platelets themselves&mdash;induce defects in platelet structure and clearance, together with a mild defect in function.</p>
]]></description>
<dc:creator><![CDATA[Dole, V. S., Matuskova, J., Vasile, E., Yesilaltay, A., Bergmeier, W., Bernimoulin, M., Wagner, D. D., Krieger, M.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.162347</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Thrombocytopenia and Platelet Abnormalities in High-Density Lipoprotein Receptor-Deficient Mice]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1116</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1111</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1117?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Ultrasonic Microbubble Destruction Stimulates Therapeutic Arteriogenesis Via the CD18-Dependent Recruitment of Bone Marrow-Derived Cells]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1117?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> We have previously shown that, under certain conditions, ultrasonic microbubble destruction creates arteriogenesis and angiogenesis in skeletal muscle. Here, we tested whether this neovascularization response enhances hyperemia in a rat model of arterial insufficiency and is dependent on the recruitment of bone marrow&ndash;derived cells (BMDCs) to treated tissues via a &beta;2 integrin (CD18)-dependent mechanism.</p>
<p><b><I>Methods and Results&mdash;</I></b> Sprague-Dawley rats, C57BL/6 wild-type mice, and C57BL/6 chimeric mice engrafted with BMDCs from either GFP<sup>+</sup> or CD18<sup>&ndash;/&ndash;</sup> mice received bilateral femoral artery ligations. Microbubbles (MBs) were intravenously injected, and one gracilis muscle was exposed to pulsed 1 MHz ultrasound (US). Rat hindlimbs exhibited significant increases in adenosine-induced hyperemia and arteriogenesis compared to contralateral controls at 14 and 28 days posttreatment. US-MB&ndash;treated wild-type C57BL/6 mice exhibited significant arteriogenesis, angiogenesis, and CD11b<sup>+</sup> monocyte recruitment; however, these responses were all completely blocked in CD18<sup>&ndash;/&ndash;</sup> chimeric mice. The number of BMDCs increased in US-MB&ndash;treated muscles of GFP<sup>+</sup> chimeric mice; however, GFP<sup>+</sup> BMDCs did not incorporate into microvessels as vascular cells.</p>
<p><b><I>Conclusion&mdash;</I></b> In skeletal muscle affected by arterial occlusion, arteriogenesis and hyperemia can be significantly enhanced by ultrasonic MB destruction. This response depends on the recruitment, but not vascular incorporation, of BMDCs via a CD18-dependent mechanism.</p>
]]></description>
<dc:creator><![CDATA[Chappell, J. C., Song, J., Klibanov, A. L., Price, R. J.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.108.165589</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Ultrasonic Microbubble Destruction Stimulates Therapeutic Arteriogenesis Via the CD18-Dependent Recruitment of Bone Marrow-Derived Cells]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>28</prism:volume>
<prism:endingPage>1122</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>1117</prism:startingPage>
<prism:section>Integrative Physiology/Experimental Medicine</prism:section>
</item>

<item rdf:about="http://atvb.ahajournals.org/cgi/content/short/28/6/1123?rss=1">
<title><![CDATA[[Integrative Physiology/Experimental Medicine] Cytochrome P450 2C9-Induced Angiogenesis Is Dependent on EphB4]]></title>
<link>http://atvb.ahajournals.org/cgi/content/short/28/6/1123?rss=1</link>
<description><![CDATA[
<p><b><I>Objective&mdash;</I></b> Cytochrome P450 (CYP) epoxygenase-derived epoxyeicosatrienoic acids (EETs) are known to stimulate angiogenesis, but the mechanisms involved are incompletely understood. Because EphB4 is involved in vascular development, the aim of this study was to investigate whether, and to what extent, EphB4 is part of the signaling cascade that results in CYP2C9-mediated angiogenesis.</p>
<p><b><I>Methods and Results&mdash;</I></b> CYP2C9 overexpression as well as stimulation with 11,12-EET (up to 48 hours) time-dependently increased EphB4 expression in endothelial cells. This effect and the activation of the EphB4 promoter were mediated by the phosphatidylinositol-3-kinase (P13-K)/Akt pathway and sensitive to the P13-K inhibitor LY 294002 as well as to simultaneous transfection with dominant-negative Akt. 11,12-EET treatment also increased EphB4 expression in isolated mouse mesenteric arteries as well as in the vessels that developed in 11,12-EET-impregnated Matrigel plugs. Moreover, the CYP2C9-stimulated formation of capillary-like structures in a modified spheroid assay was markedly attenuated by EphB4 downregulation (antisense oligonucleotides). Using a parallel approach in vivo, the inclusion of siRNA directed against EphB4 in EET-impregnated Matrigel plugs prevented endothelial cell invasion and vascularization.</p>
<p><b><I>Conclusions&mdash;</I></b> Our data indicate that EphB4 is a critical component of the CYP2C9- and 11,12-EET-activated signaling cascade that promotes angiogenesis in vitro as well as in vivo.</p>
]]></description>
<dc:creator><![CDATA[Webler, A. C., Popp, R., Korff, T., Michaelis, U. R., Urbich, C., Busse, R., Fleming, I.]]></dc:creator>
<dc:date>2008-05-21</dc:date>
<dc:identifier>info:doi/10.1161/ATVBAHA.107.161190</dc:identifier>
<dc:title><![CDATA[[Integrative Physiology/Experimental Medicine] Cytochrome P450 2C9-Induced Angiogenesis Is Dependent on EphB4]]></dc:title>
<dc:publisher>American Heart Association</dc:publisher